glp 1 comparison GLP-1 Agonists for Weight Loss: A Side-by-Side GLP-1 Medications: Everything You Need

5 The ADA/EASD statement features use of the sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, which have now been shown to provide cardiovascular and mortality benefit in populations with diabetes who are at risk of or have cardiovascular disease (CVD)

Further, whilst efpeglenatide was associated with a relative risk reduction of 30% in those who were not on SGLT2 inhibitors at trial entry (HR 0.70

Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure

Intensive glucose control and risk of cancer in patients with type 2 diabetes

Various cells in the bone microenvironment secrete DPP-4, including osteoclasts, bone marrow adipose tissue, and immune cells [2]

BMJ 2023;382:p2019.Article 72